More on RZLT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.58 |
|
|||
| Open | $4.53 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $4.71 | ||||
| Day Low | $4.24 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 2,093,711 | ||||
- Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
- Rezolute (RZLT) PT Raised to $14 at Maxim Group
- Rezolute (RZLT) Reiterated at Neutral by Cantor Fitzgerald
- Citizens Upgrades Rezolute (RZLT) to Market Outperform
- Rezolute (RZLT) PT Raised to $6 at Wedbush
- Form 8-K Rezolute, Inc. For: Jun 02
- Rezolute reports interim results from phase 3 tumor hyperinsulinism trial
- Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
- Form SCHEDULE 13G Rezolute, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
- Rezolute (RZLT) PT Raised to $10 at Maxim Group
Entities mentioned with RZLT
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- S3 | View Related Stories »
- Show More...
